Peginterferon alpha-2b plus ribavirin with or without amantadine [correction of amantidine] for the treatment of non-responders to standard interferon and ribavirin.

abstract：BACKGROUND:Increasing efavirenz (EFV) dose from 600 mg to 800 mg daily has been suggested with concomitant rifampicin (RFN), as induction of cytochrome P450 isoenzymes may reduce EFV plasma concentrations. METHODS:Individuals from the CIPRA-South Africa cohort taking EFV-based antiretroviral therapy with concomitant t...

journal_title：Antiviral therapy

authors： Orrell C,Cohen K,Conradie F,Zeinecker J,Ive P,Sanne I,Wood R

更新日期：2011-01-01 00:00:00

abstract：BACKGROUND:The tuberculosis (TB) mortality rate of registered TB patients in Malawi is 23%, and 59% of the deaths occur in the first 2 months of treatment. HIV-related complications appear to be an important cause. Starting antiretroviral therapy early during tuberculosis treatment may improve outcome but problems ofte...

journal_title：Antiviral therapy

authors： van Oosterhout JJ,Kumwenda JJ,Beadsworth M,Mateyu G,Longwe T,Burger DM,Zijlstra EE

更新日期：2007-01-01 00:00:00

abstract：BACKGROUND:With the advent of the protease inhibitors boceprevir and telaprevir a novel therapy approach for HCV genotype 1 infected subjects has become standard of care. Quantification of HCV viral load (VL) represents an important predictor of treatment response. METHODS:Two different real-time PCR platforms, the CO...

journal_title：Antiviral therapy

authors： Taylor N,Haschke-Becher E,Greil R,Strasser M,Oberkofler H

更新日期：2014-01-01 00:00:00

abstract：:HBV is a hepatotropic and non-cytopathic virus that causes more than one million deaths annually from liver cirrhosis and hepatocellular carcinoma. As the virus itself is non-cytopathic, it is widely accepted that both viral control and liver pathology are mediated by the host immune system. Until recently, the focus ...

journal_title：Antiviral therapy

authors： Bertoletti A,Maini MK,Ferrari C

更新日期：2010-01-01 00:00:00

abstract：OBJECTIVE:In patients with a chronic asymptomatic HIV-1 infection and >200 CD4+ T-cells/microl, the optimal timing of highly active antiretroviral therapy (HAART) initiation is unclear. It involves a trade-off between a potentially reduced risk of mortality, when started earlier in the course of infection, and an earli...

journal_title：Antiviral therapy

authors： Locadia M,van Grieken RA,Prins JM,de Vries HJ,Sprangers MA,Nieuwkerk PT

更新日期：2006-01-01 00:00:00

abstract：:Drug-drug interactions in HIV therapy have been known to the clinic from earliest days of HIV treatment. Hundreds of well-designed pharmacokinetic studies have been performed in either HIV-infected patients or, mostly, in healthy volunteers. Case reports generally are graded lower in terms of evidence-based medicine b...

journal_title：Antiviral therapy

authors： Burger D,Back D

更新日期：2013-01-01 00:00:00

abstract：:There is a need for new antiretroviral drugs with activity against HIV isolates resistant to currently available agents and improved short and long-term tolerability profiles. Clinical trial designs for nucleotide and nucleoside reverse transcriptase inhibitors (NRTIs) are restricted by the characteristics of these ag...

journal_title：Antiviral therapy

authors： Wainberg MA,Sawyer JP,Montaner JS,Murphy RL,Kuritzkes DR,Raffi F

更新日期：2005-01-01 00:00:00

abstract：BACKGROUND:In patients with chronic HCV infection, an association between IL28B genotype and insulin-resistance (IR), known predictors of sustained virological response (SVR) to pegylated interferon (PEG-IFN) and ribavirin (RBV) therapy, has been reported. The aim of this study was to investigate the association of IR ...

journal_title：Antiviral therapy

authors： Degasperi E,Valenti L,Aghemo A,De Francesco R,Rumi M,Soffredini R,Donnici L,Cheroni C,Fargion S,Zanoni V,Orsi E,Colombo M

更新日期：2014-01-01 00:00:00

abstract：:Since the first report of severe fever with thrombocytopenia syndrome (SFTS) in China, diagnostic methods have evolved. Despite definitive diagnoses, SFTS management has focused on prevention and supportive care. Although conservative treatment is effective for mild cases, there is an urgent need for an effective ther...

journal_title：Antiviral therapy

authors： Kim UJ,Kim DM,Ahn JH,Kang SJ,Jang HC,Park KH,Jung SI

更新日期：2016-01-01 00:00:00

abstract：:Here, we describe a case of an HIV-infected patient with right lower limb oedema that appeared after initiation of tenofovir and emtricitabine treatment. The patient was fully investigated by serial heart and vessel echo-Doppler examination. Oedema of the lower limb was attributed to a transient drug-induced fivefold ...

journal_title：Antiviral therapy

authors： Periard D,Yerly P,Hayoz D,Mazzolai L,Widmeier A,Cavassini M

更新日期：2009-01-01 00:00:00

abstract：:Ribavirin is a guanosine analogue that has little antiviral activity when used alone, but considerably enhances the efficacy of conventional and pegylated interferon in the treatment of hepatitis C virus (HCV). The precise mode of action of ribavirin is not fully understood; however, it is crucial for the achievement ...

journal_title：Antiviral therapy

authors： Dusheiko G,Nelson D,Reddy KR

更新日期：2008-01-01 00:00:00

abstract：:Delayed and variable antibody responses to HCV make it difficult to diagnose acute HCV infection reliably. Immunoglobulin (Ig)M and IgG anti-HCV may be observed simultaneously as disease persists. IgM plays a key role in mixed cryoglobulinemia (MC), an immune complex disease strongly associated with persistent HCV inf...

journal_title：Antiviral therapy

authors： Dustin LB,Charles ED

更新日期：2012-01-01 00:00:00

abstract：BACKGROUND:The H275Y neuraminidase mutation conferring oseltamivir resistance has been reported in several pandemic A/H1N1 (pH1N1) isolates. We sought to evaluate transmission of this mutant virus through the direct contact and the airborne (aerosol and droplet) routes in the ferret model. METHODS:Groups of four ferre...

journal_title：Antiviral therapy

authors： Hamelin ME,Baz M,Bouhy X,Beaulieu E,Dubé K,Mallett C,Boivin G

更新日期：2011-01-01 00:00:00

abstract：BACKGROUND:Little is known about pregnancy patterns and levels of HIV RNA in HIV-infected women conceiving on highly active antiretroviral therapy (HAART) with non-suppressed viral load (VL), nor about their therapeutic management. METHODS:Linear mixed models were fitted to study changes in VL and potential associated...

journal_title：Antiviral therapy

authors： European Collaborative Study.

更新日期：2010-01-01 00:00:00

abstract：BACKGROUND:Rilpivirine (RPV), a non-nucleoside reverse transcriptase inhibitor (NNRTI), was approved for HIV-1 infected, antiretroviral treatment-naive adults based on data from two Phase III trials. In the screening population, the prevalence of 49 NNRTI resistance-associated mutations (RAMs) and the impact of allowed...

journal_title：Antiviral therapy

authors： Vingerhoets J,Rimsky L,Van Eygen V,Nijs S,Vanveggel S,Boven K,Picchio G

更新日期：2013-01-01 00:00:00

abstract：BACKGROUND:Human cytomegalovirus (HCMV) infections remain a major problem in immunocompromised patients. Three antiviral agents, ganciclovir (GCV), foscarnet (FOS) and cidofovir (CDV), are currently approved for the treatment of HCMV infections. They all target the viral DNA polymerase and are associated with significa...

journal_title：Antiviral therapy

authors： Drouot E,Piret J,Boivin G

更新日期：2016-01-01 00:00:00

abstract：BACKGROUND:Little is known about the efficacy, safety and tolerability of pegylated interferon plus ribavirin treatment in patients with chronic hepatitis Cvirus (HCV) infection and histologically proven fully established cirrhosis. We aimed here to evaluate the safety of this regimen in such patients and to identify b...

journal_title：Antiviral therapy

authors： Roffi L,Colloredo G,Pioltelli P,Bellati G,Pozzpi M,Parravicini P,Bellia V,Del Poggio P,Fornaciari G,Ceriani R,Ramella G,Corradi C,Rossini A,Bruno S,Gruppo Epatologico Lombardo.

更新日期：2008-01-01 00:00:00

abstract：BACKGROUND:The combination of pegylated interferon (PEG-IFN) plus ribavirin (RBV) is the standard of care for hepatitis C virus (HCV) treatment in HIV-coinfected individuals. In 2007, abacavir (ABC)-based antiretroviral therapy was, for the first time, reported to be associated with early virological failure during HCV...

journal_title：Antiviral therapy

authors： Laufer N,Laguno M,Perez I,Cifuentes C,Murillas J,Vidal F,Bonet L,Veloso S,Gatell JM,Mallolas J

更新日期：2008-01-01 00:00:00

abstract：:Chronic infection with HBV or HCV can lead to the development of hepatocellular carcinoma (HCC). The major risk factors for HBV-related HCC are persistent presence of hepatitis B e antigen (HBeAg) and/or high serum HBV DNA levels, and cirrhosis. The major risk factor for HCV-related HCC is cirrhosis. One randomized do...

journal_title：Antiviral therapy

authors： Kwon H,Lok AS

更新日期：2011-01-01 00:00:00

abstract：BACKGROUND:Single-drug class regimens with nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) are generally not recommended as initial therapy because they are inferior compared with therapy with two NRTIs plus efavirenz. However, triple-NRTI combinations can be useful in specific circumstances such as in t...

journal_title：Antiviral therapy

authors： Sprenger HG,Bierman WF,van der Werf TS,Gisolf EH,Richter C

更新日期：2014-01-01 00:00:00

abstract：:Although chronic HBV infection is the leading cause of chronic liver disease and death worldwide, there are substantial differences in its clinical courses regarding prevalence, mode of transmission, characteristics of each phase, responses to antiviral therapy, and development of cirrhosis and hepatocellular carcinom...

journal_title：Antiviral therapy

authors： Kim BK,Revill PA,Ahn SH

更新日期：2011-01-01 00:00:00

abstract：BACKGROUND:Endothelial progenitor cells (EPCs) are involved in the endothelium repair. Low circulating EPC levels are predictive of cardiovascular events in HIV-negative subjects. The impact of HIV infection on EPCs, and the role of EPCs in HIV-associated cardiovascular disease, is not known. We hypothesized that circu...

journal_title：Antiviral therapy

authors： Papasavvas E,Hsue P,Reynolds G,Pistilli M,Hancock A,Martin JN,Deeks SG,Montaner LJ

更新日期：2012-01-01 00:00:00

abstract：OBJECTIVE:To assess the effect of interleukin (IL)-2 combined with highly active antiretroviral therapy (HAART) on HIV-1 pro-viral DNA quantification in HIV-1-infected patients with CD4<200/mm3. PATIENTS AND METHODS:Seventy patients with CD4<200 cells/mm3 and CV<1000 copies/ml were enrolled in a 6-month randomized con...

journal_title：Antiviral therapy

authors： Delaugerre C,Gourlain K,Tubiana R,Carcelain G,Marcelin AG,Chouquet C,Mouroux M,Duvivier C,Autran B,Costagliola D,Katlama C,Calvez V

更新日期：2003-06-01 00:00:00

abstract：BACKGROUND:This study evaluates the added benefit when estimating antiretroviral drug resistance of combining all available resistance test results in a cumulative genotype relative to using the latest genotype alone. METHODS:The prevalence of resistance and genotypic sensitivity scores (GSS) predicted by the latest a...

journal_title：Antiviral therapy

authors： Garcia F,Alvarez M,Fox Z,Garcia-Diaz A,Guillot V,Johnson M,Chueca N,Phillips A,Hernández-Quero J,Geretti AM

更新日期：2011-01-01 00:00:00

abstract：BACKGROUND:No data are available on the clinical presentation and virological pattern in the case of failure of interferon (IFN)-free regimens in patients with genotype-3h. In this paper authors identified the virological and clinical characteristics of patients with genotype-3h treated with suboptimal or not indicated...

journal_title：Antiviral therapy

authors： Minichini C,Starace M,De Pascalis S,Macera M,Occhiello L,Caroprese M,Vitrone M,Iovinella V,Guerrera B,Masarone M,Coppola N

更新日期：2018-01-01 00:00:00

abstract：BACKGROUND:Porcine reproductive and respiratory syndrome virus (PRRSV) causes significant economic loss in the swine industry. Currently, there is no effective way to prevent PRRSV infection. Sodium tanshinone IIA sulfonate (STS), a natural compound derived from Salvia miltiorrhiza, was shown to possess anti-PRRSV acti...

journal_title：Antiviral therapy

authors： Sun N,Li E,Wang Z,Zhao J,Wang S,He J,Bai Y,Li H

更新日期：2014-01-01 00:00:00

abstract：BACKGROUND:Across sub-Saharan Africa, men who have sex with men (MSM) and transgender women (TGW) have disproportionately poor HIV treatment outcomes. Stigma and criminalization create barriers to health-care engagement and adherence to antiretroviral therapy (ART), potentially promoting the development of HIV drug res...

journal_title：Antiviral therapy

authors： Crowell TA,Kijak GH,Sanders-Buell E,O'Sullivan AM,Kokogho A,Parker ZF,Lawlor J,Polyak CS,Adebajo S,Nowak RG,Baral SD,Robb ML,Charurat ME,Ake JA,Ndembi N,Tovanabutra S,TRUST\/RV368 Study Group.

更新日期：2019-01-01 00:00:00

abstract：:Although zidovudine (ZDV) is effective in HIV-1-infected patients, the duration of its efficacy may be short when treatment is started in advanced HIV disease. This pilot prospective case-control study was designed to evaluate the combination of ZDV plus didanosine [ddI] compared with ZDV monotherapy as an initial the...

journal_title：Antiviral therapy

authors： Gatell JM,Leal M,Mallolas J,Vidal C,Pumarola T,Parra R,Padró S,Caruz A,Falgueras T,Rey C,Sánchez-Quijano A,Torres Y,Lissen E,Jiménez de Anta MT,Soriano E

更新日期：1996-04-01 00:00:00

abstract：BACKGROUND:Ribavirin augments sustained virological response when administered with pegylated interferon for the treatment of chronic HCV infection. The impact of ribavirin plasma concentration on outcome in individuals receiving interferon-free regimens has not been evaluated. METHODS:Stored plasma samples were retri...

journal_title：Antiviral therapy

authors： Martinello M,Schteinman A,Alavi M,Williams K,Dore GJ,Day R,Matthews GV

更新日期：2016-01-01 00:00:00

abstract：BACKGROUND:Unique serum anti-E1E2 antibodies were shown to be associated with spontaneous recovery or predictive of sustained virological response (SVR) in patients with chronic hepatitis C receiving pegylated interferon/ribavirin (PEG-IFN/RBV) therapy. The objectives were to establish the relationship between pretreat...

journal_title：Antiviral therapy

authors： Arnaud C,Pradat P,Spaziante M,Berthillon P,Maynard M,Taliani G,Chemin I,Trépo C,Petit MA

更新日期：2013-01-01 00:00:00